<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vitamin and mineral deficiencies in inflammatory bowel disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vitamin and mineral deficiencies in inflammatory bowel disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vitamin and mineral deficiencies in inflammatory bowel disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dale Young Lee, MD, MSCE</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melvin B Heyman, MD, MPH</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Individuals with inflammatory bowel disease (IBD), and particularly those with Crohn disease, are at risk for a variety of nutritional deficiencies because of decreased nutrient intake, malabsorption, increased energy expenditure, and/or increased losses. The most common deficiencies are iron, vitamin D, vitamin B12, and zinc  (<a class="graphic graphic_table graphicRef72725" href="/z/d/graphic/72725.html" rel="external">table 1</a>). Some of these micronutrient deficiencies are more prominent at disease diagnosis, while other deficiencies persist or even worsen during treatment.</p><p>Several factors contribute to deficits in energy and protein in IBD. Patients with active disease often have reduced nutrient intake due to anorexia, which is associated with disease activity and may be mediated by proinflammatory cytokines, such as tumor necrosis factor-alpha. Malabsorption, maldigestion, increased energy expenditure, and gastrointestinal protein loss also contribute to deficiencies of energy and protein and are usually correlated with disease activity. Similar mechanisms contribute to vitamin and mineral deficiencies in IBD. In addition, the activity and location of a patient's intestinal disease determines their risk for specific micronutrient deficiencies because some nutrients are digested and absorbed in specific segments of the gastrointestinal tract.</p><p>Vitamin and mineral deficiencies in adults and children with IBD will be reviewed here. Other aspects of nutrition in patients with IBD are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">"Growth failure and pubertal delay in children with inflammatory bowel disease"</a>.) – Focuses on pathogenesis, assessment, and management of undernutrition and pubertal delay in children with IBD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents"</a>.) – Includes discussion of exclusive enteral nutrition and supplemental enteral nutrition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13924.html" rel="external">"Nutrition and dietary management for adults with inflammatory bowel disease"</a>.) – Includes discussion of specific diets (eg, specific carbohydrate diet [SCD]).</p><p></p><p class="headingAnchor" id="H1460685023"><span class="h1">RISK FACTORS FOR NUTRIENT DEFICIENCIES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease activity</strong> – Individuals with newly diagnosed or active IBD are at greater risk for nutrient deficiencies through several different mechanisms. First, intestinal inflammation is associated with malabsorption and maldigestion, which contribute to deficiencies of energy, protein, and micronutrients. Second, patients may have anorexia and increased energy expenditure, which are mediated by the inflammatory cytokines that are associated with active disease. Third, they may voluntarily limit their intake of foods that exacerbate their symptoms. Finally, these inflammatory mediators also specifically interfere with absorption or utilization of certain nutrients, especially iron and vitamin D. (See <a class="local">'Iron'</a> below and <a class="local">'Vitamin D'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease location</strong> – The risk for specific nutrient deficiencies is related to the location and extent of the mucosal inflammation or surgical resection within the intestinal tract. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Terminal ileum</strong> – Active disease may lead to deficiencies of vitamin B12 or fat-soluble vitamins</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Proximal small intestine</strong> – Active disease interferes with iron and calcium absorption</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diffuse small bowel disease</strong> – Extensive disease with profuse diarrhea may lead to zinc deficiency</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe colonic disease</strong> – Colon mucosal ulceration may lead to ongoing blood loss and iron deficiency</p><p></p><p class="bulletIndent1">These mechanisms are discussed in the sections on each of these deficiencies below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growing children</strong> – Due to increased requirements for growth and development, growing children are at greater risk for nutrient deficiencies. Children have greater needs for micronutrients and minerals such as calcium. For example, the recommended dietary allowance (RDA) of calcium for children ages 9 to 18 is 1300 mg per day, while the RDA for adults is 1000 to 1200 mg calcium per day [<a href="#rid1">1</a>]. Nutrients directly impacting bone health and subsequently linear growth include calcium, magnesium, copper, phosphorus, iron, and vitamin D. Whereas the maintenance of bone health is a goal in adults with IBD, growth in children requires accrual of bone and muscle mass. Importantly, adequate control of inflammation is critical as inflammatory cytokines have a direct impact on bone formation and muscle formation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fat malabsorption</strong> – Deficiencies of fat-soluble vitamins (vitamins A, D, E, and K) are most likely to occur in patients with fat malabsorption. Fat malabsorption may be caused by bile acid deficiency due to terminal ileal disease or resection (because bile acids undergo active resorption in the terminal ileum) or by the use of medicines, such as <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a>, that bind bile acids. As a result, these deficiencies occur primarily in patients with Crohn disease and active terminal ileal disease or resection. Vitamin D or A deficiencies are most common, while <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> and K deficiencies are rare. (See <a class="local">'Vitamin D'</a> below and <a class="local">'Vitamin A'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical resection</strong> – A large proportion of patients with IBD, particularly those with Crohn disease, eventually require surgical resection of some portion of the bowel. Surgery for patients with Crohn disease often involves the ileum and portions of the colon. The terminal ileum is the site of vitamin B12 absorption, and larger ileal resections (ie, greater than 100 cm) can disrupt the enterohepatic circulation and result in intestinal losses of bile salts. The consequences may include choleretic diarrhea, steatorrhea, and fat-soluble vitamin deficiencies. In general, jejunal resections are less likely to result in nutrient deficiencies than ileal resections.</p><p></p><p class="headingAnchor" id="H178481258"><span class="h1">ANSWERS TO COMMON CLINICAL QUESTIONS</span><span class="headingEndMark"> — </span>The following questions often arise during the care of an IBD patient:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Do all patients with IBD need a multivitamin supplement?</strong> – No. The most important strategy to address micronutrient deficiencies is to treat the patient's underlying disease to minimize inflammation and any associated malabsorption and anorexia. Once remission is achieved, most patients can get adequate quantities of micronutrients from food sources if they have a well-balanced diet, including recommended proportions of protein, fruits, vegetables, and fortified dairy products, except that vitamin D supplementation is commonly needed (see <a class="local">'Vitamin D'</a> below). Patients with specific, pronounced deficiencies may require other vitamin or mineral supplements, tailored to their individual needs. (See  <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">"Healthy diet in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5357.html" rel="external">"Dietary history and recommended dietary intake in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Are patients who follow the specific carbohydrate diet (SCD) or other restriction diets at risk for micronutrient deficiencies?</strong> – The risk depends on the individual patient; patients who choose to follow the SCD should have dietary counseling and close follow-up to ensure adequate nutrition. The SCD is a restrictive diet that is postulated to have beneficial effects on inflammation from IBD and has generated broad interest from patients and their families. The diet involves the elimination of all grains, refined sugars, "processed" foods, and the majority of dairy products (although yogurt fermented for 24 hours and certain hard cheeses are allowed). Limited data from case series have suggested that the SCD has a beneficial effect on inflammation in IBD [<a href="#rid2">2,3</a>]. However, concerns have arisen about the possibility of weight loss, negative psychosocial impact, and risks for nutrient deficiencies for patients following the SCD. In case series in children following the SCD with appropriate guidance from a dietitian, nutrient intake was similar to that in a healthy reference population [<a href="#rid4">4</a>]. However, there was considerable variation in nutrient adequacy within this patient population, similar to healthy populations. Thus, for any patient who chooses to follow an exclusion diet, it is important to provide counseling by a dietitian and ongoing monitoring of nutritional status.</p><p></p><p class="bulletIndent1">One study found that children managed with partial enteral nutrition plus a whole-food elimination diet (termed the Crohn Disease Exclusion Diet) had better adherence to the regimen and equivalent steroid-free remission rates compared with those managed with exclusive enteral nutrition [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Partial enteral nutrition with specific exclusion diet'</a>.)</p><p></p><p class="bulletIndent1">Other dietary strategies for patients with IBD, including lactose avoidance and elimination diets, are discussed separately. Patients who follow any restriction diet for IBD should have close follow-up with a dietitian and gastroenterologist. (See  <a class="medical medical_review" href="/z/d/html/13924.html" rel="external">"Nutrition and dietary management for adults with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>What is the optimal route of iron therapy for patients with IBD?</strong> – Both enteral and parenteral routes are acceptable, and the choice depends on the characteristics of the individual patient, including the severity of the iron deficiency and tolerance of oral iron therapy. Experimental evidence from animal models suggests that enteral iron supplementation increases oxidative stress and exacerbates intestinal inflammation. In humans with IBD, low-dose enteral iron supplementation (60 mg elemental iron/day) has not been shown to significantly increase disease activity [<a href="#rid6">6,7</a>]. Moreover, both enteral and intravenous (IV) iron supplementation are effective at increasing serum hemoglobin concentrations. A clinical approach is outlined below. (See <a class="local">'Iron therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is there a role for antioxidant vitamins for therapy of IBD?</strong> – Probably not. Patients with Crohn disease have biomarkers that suggest greater oxidative stress than healthy individuals, even at times when their disease is relatively quiescent. As an example, one study reported that adult patients with Crohn disease had elevated oxidative stress (as measured by breath pentane and ethane output) compared with healthy controls [<a href="#rid8">8</a>]. Depletion of dietary antioxidants has been suggested as a possible mechanism. A few randomized trials using supplementation of antioxidants (vitamins A and E, <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a>, fish oil, omega-3 fatty acids) in various combinations generally reduced measures of oxidative stress but did not affect disease activity [<a href="#rid9">9-11</a>].</p><p></p><p class="bulletIndent1">Thus, there is no direct evidence that supplementation with antioxidant vitamins can reduce inflammation in patients with IBD. Moreover, high-dose supplementation of vitamins A or E may have adverse effects on bone or cardiovascular health, respectively, and is not recommended [<a href="#rid12">12</a>]. (See <a class="local">'Vitamin A'</a> below and <a class="local">'Vitamin E'</a> below.)</p><p></p><p class="headingAnchor" id="H2132435631"><span class="h1">LABORATORY MONITORING FOR NUTRIENT DEFICIENCIES</span><span class="headingEndMark"> — </span>Laboratory monitoring of nutritional status for patients with IBD depends on the patient's disease activity and location, general nutritional status, and specific risk factors such as exclusive parenteral or enteral nutrition. In our practice, we use the following approach:</p><p></p><p class="headingAnchor" id="H411665405"><span class="h2">Routine monitoring</span><span class="headingEndMark"> — </span>In patients with quiescent IBD, we perform routine monitoring for nutritional deficiencies every 6 to 12 months  (<a class="graphic graphic_table graphicRef66288" href="/z/d/graphic/66288.html" rel="external">table 2</a>). We perform this monitoring more frequently for patients with active disease, those receiving targeted nutrient supplementation, and for growing children. Routine tests are:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count (CBC) with red blood cell parameters to screen for iron deficiency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), as markers of inflammatory status</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum albumin, as a marker of inflammatory status and disease activity rather than protein intake</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum 25-hydroxyvitamin D</p><p></p><p class="headingAnchor" id="H3279824143"><span class="h2">Conditional tests</span><span class="headingEndMark"> — </span>The following tests are not routinely needed but should be performed in selected patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Ferritin, serum iron, total iron-binding capacity, transferrin saturation – To be checked at baseline, then as needed for patients with anemia of unclear etiology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin B12 – For patients with Crohn disease involving the ileum or with an ileal resection, at least every one to two years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calcium, phosphorus, magnesium, and potassium – For patients with chronic diarrhea or active small bowel disease, or during refeeding in severely undernourished patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamins A and E, and prothrombin time (PT) or international normalized ratio (INR; to assess vitamin K status) – For patients at risk for fat malabsorption, eg, those with active terminal ileal disease or resection, or those using medicines such as <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> that bind bile acids (see <a class="local">'Risk factors for nutrient deficiencies'</a> above). If hyperlipidemia is present, the results for <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> should be adjusted for serum lipids. (See  <a class="medical medical_review" href="/z/d/html/2582.html" rel="external">"Overview of vitamin E"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Zinc – For patients with excessive enteral losses due to ostomies, fistulas, or profuse diarrhea (eg, &gt;8 watery stools daily).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Folate – For patients who are taking a medication that may affect folate status (eg, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>) and also have other symptoms or screening laboratory abnormalities (eg, anemia).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fecal calprotectin – For patients without elevation in serologic markers of inflammation but who have symptoms suggesting active intestinal inflammation.</p><p></p><p>We do not usually test for deficiencies of <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a> or copper unless a patient has profuse diarrhea (eg, &gt;8 watery stools daily, or ostomy output &gt;1500 mL/day or &gt;20 mL/kg/day in children) and exhibits other signs of nutritional deficiency or other risk factors for these deficiencies, such as insufficient intake through parenteral or enteral nutrition. (See <a class="local">'Other'</a> below.)</p><p class="headingAnchor" id="H3897218179"><span class="h1">CONSIDERATIONS FOR PATIENTS WITH ANEMIA</span><span class="headingEndMark"> — </span>Anemia is reported in approximately 16 percent of outpatients and up to 70 percent of inpatients with IBD, with particularly high rates in children [<a href="#rid13">13-15</a>]. Potential contributors are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron deficiency</strong> – Iron deficiency is probably the most important contributor to anemia for many patients with IBD. (See <a class="local">'Iron'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia of chronic inflammation</strong> – Another important mechanism is anemia of chronic inflammation (previously known as anemia of chronic disease), which is characterized by suppressed erythropoietin production and altered iron metabolism caused by proinflammatory cytokines [<a href="#rid16">16</a>]. Hepcidin, a key hormonal regulator of iron homeostasis, is increased and negatively regulates iron absorption from the gastrointestinal tract [<a href="#rid17">17,18</a>]. For patients with this disorder, oral iron is often ineffective, whereas intravenous (IV) iron is sometimes effective and is generally safe [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a> and  <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Oral versus IV iron'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin B12 or folate deficiency</strong> – Some patients with IBD are at risk for vitamin B12 or <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> deficiencies, both of which cause a macrocytic anemia. Factors contributing to vitamin B12 deficiency include disease or resection of the terminal ileum, gastritis, and bacterial overgrowth. Patients on <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> therapy are at increased risk for folic acid deficiency. (See <a class="local">'Vitamin B12'</a> below and <a class="local">'Folic acid'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced anemia</strong> – A variety of drugs may cause anemia, including <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> (due to multiple mechanisms) or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and thiopurines (due to bone marrow suppression), which are often used for treatment of IBD. (See  <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease", section on 'Sulfasalazine'</a> and  <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">COMMON DEFICIENCIES</span></p><p class="headingAnchor" id="H2049722200"><span class="h2">Iron</span><span class="headingEndMark"> — </span>Iron deficiency is a common nutritional deficiency in IBD and is probably the most important contributor to anemia in this population [<a href="#rid13">13</a>]. However, patients may have other contributors to anemia, which complicate the evaluation and management of iron deficiency. (See <a class="local">'Considerations for patients with anemia'</a> above.)</p><p class="headingAnchor" id="H2856054265"><span class="h3">Prevalence and risk factors</span><span class="headingEndMark"> — </span>Literature reviews report iron deficiency in 35 to 90 percent of adults and 30 to 88 percent of children with IBD [<a href="#rid14">14,21,22</a>]. Iron deficiency has a significant negative impact on quality of life and can lead to developmental and cognitive abnormalities in children and adolescents [<a href="#rid23">23</a>], and iron repletion can improve quality of life [<a href="#rid22">22</a>].</p><p>Several mechanisms contribute to iron deficiency in IBD. First, acute or chronic intestinal bleeding is a common source of iron loss. Second, patients with duodenal disease are at increased risk because iron is predominantly absorbed in the duodenum. Third, inflammation directly inhibits erythropoiesis and acts via upregulation of hepcidin to decrease enteric absorption of iron and also decrease mobilization of iron stores from the liver and spleen.</p><p class="headingAnchor" id="H2130974841"><span class="h3">Assessment</span><span class="headingEndMark"> — </span>Patients with IBD should be screened for iron deficiency periodically by measuring a complete blood count (CBC) with both C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) to provide context on inflammatory status. In the initial evaluation for anemia, it may be helpful to include serum iron, ferritin, and total iron-binding capacity to help distinguish between iron deficiency and other causes of anemia. (See <a class="local">'Considerations for patients with anemia'</a> above.)</p><p>A low serum ferritin is always consistent with iron deficiency, but normal or elevated ferritin does not exclude iron deficiency. This is because ferritin is an acute phase reactant and may be falsely normal in the setting of inflammation, including in patients with active IBD or acute infection. In patients without biochemical or clinical evidence of inflammation, iron deficiency is indicated by a serum ferritin &lt;30 mcg/L. In the presence of inflammation (as suggested by an elevated CRP or ESR), serum ferritin levels below 100 mcg/L should be considered abnormal [<a href="#rid14">14,24</a>]. In addition, serum ferritin may be falsely normal in a patient with hypoalbuminemia. Fecal calprotectin may have value as a surrogate marker of intestinal inflammation. (See  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Stool tests'</a>.)</p><p>In patients with a microcytic anemia and low serum ferritin, iron deficiency is the most likely cause. The diagnosis is confirmed if the laboratory abnormalities resolve with iron therapy.</p><p>In patients with anemia that does not fit these characteristics and/or that does not respond to iron therapy, other causes of anemia should be considered. These include anemia of chronic inflammation (anemia of chronic disease), vitamin B12 or folate deficiency, and underlying hemoglobinopathy (eg, thalassemia). Other tests of iron status may help to distinguish between these disorders  (<a class="graphic graphic_table graphicRef65701" href="/z/d/graphic/65701.html" rel="external">table 3</a>) but may not be definitive, especially in anemia caused by mixed mechanisms. (See <a class="local">'Considerations for patients with anemia'</a> above.)</p><p>Interpretation of laboratory tests in patients with anemia is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5925.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis", section on 'Evaluation for suspected iron deficiency anemia'</a> and  <a class="medical medical_review" href="/z/d/html/5350.html" rel="external">"Iron requirements and iron deficiency in adolescents", section on 'Evaluation and presumptive diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H2474250937"><span class="h3">Iron therapy</span><span class="headingEndMark"> — </span>A presumptive diagnosis of iron deficiency or iron deficiency anemia can be made after the laboratory testing outlined above and is an indication for iron therapy. A definitive diagnosis can be made if the hemoglobin and ferritin normalize after iron therapy.</p><p>Patients with IBD present unique challenges regarding iron therapy. Either oral or intravenous (IV) iron therapy may be appropriate, and the choice depends on the characteristics of the individual patient, including the severity of the iron deficiency and tolerance of oral therapy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – We suggest the following approach to iron supplementation in patients with IBD and evidence of iron deficiency:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with mild IBD activity and mild or moderate anemia (hemoglobin 10 to 12 g/dL in children and women or 10 to 13 g/dL in men), we suggest iron supplementation by the oral route as an initial trial. Specific suggestions for initial treatment are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15647.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Treatment", section on 'Oral iron therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Choice of oral preparation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For adult patients with moderate to severe IBD activity or severe anemia (hemoglobin &lt;10 g/dL), or for those who do not tolerate or respond appropriately to oral iron, we suggest IV supplementation. Specific suggestions for the choice of agent, use of a test dose and/or premedication, and calculation of the dose of iron are presented in depth elsewhere. Blood transfusion is generally reserved for patients with severe anemia with symptoms or hemodynamic instability. (See  <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Intravenous iron'</a> and  <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Severe/life-threatening anemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children and adolescents with IBD, we suggest the same approaches as adults [<a href="#rid15">15</a>]. The safety of IV iron in pediatric patients has been demonstrated [<a href="#rid25">25-28</a>]. (See  <a class="medical medical_review" href="/z/d/html/15647.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Treatment", section on 'Oral iron therapy'</a> and  <a class="medical medical_review" href="/z/d/html/5350.html" rel="external">"Iron requirements and iron deficiency in adolescents", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the anemia fails to respond, or only partially responds, to treatment with IV iron, this may indicate either an erroneous diagnosis of iron deficiency or the presence of a component of the anemia of chronic inflammation (anemia of chronic disease). In such cases, further treatment of active inflammation and/or addition of erythropoietin to the regimen may result in improvement of the anemia [<a href="#rid29">29,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a>.)</p><p></p><p>The above approach is based on the following considerations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral iron</strong> – Oral iron therapy is convenient and inexpensive. However, its use is limited by the following considerations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Many individuals with IBD are intolerant of oral iron preparations, especially those with moderate or severe disease activity [<a href="#rid31">31-33</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>High doses of oral iron may worsen IBD disease activity [<a href="#rid31">31</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with IBD may have ongoing inflammation that may interfere with iron absorption</p><p class="bulletIndent2"><span class="glyph">•</span>Oral iron is not effective if the anemia is caused by chronic inflammation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV iron</strong> – Because of these potential limitations of oral iron therapy, IV iron therapy is appropriate for many patients with IBD, as suggested by several expert panels [<a href="#rid15">15,24,34-37</a>]. Numerous studies have demonstrated the safety and efficacy of various IV iron preparations in these patients [<a href="#rid19">19,29,38</a>]. In Europe, IV iron is standard first-line therapy for IBD-associated iron deficiency [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Inflammatory bowel disease and iron-restricted erythropoiesis'</a>.)</p><p></p><p class="headingAnchor" id="H3842258997"><span class="h2">Vitamin D</span><span class="headingEndMark"> — </span>Vitamin D insufficiency is common in patients with IBD. In one study, 25 percent of adults with Crohn disease had deficient serum 25-hydroxyvitamin D (calcidiol) concentrations (&lt;10 ng/mL) [<a href="#rid40">40</a>]. Studies in children report that 6 to 36 percent of children with IBD have deficient 25-hydroxyvitamin D concentrations (&lt;15 ng/mL) [<a href="#rid41">41-43</a>]. Vitamin D deficiency is one of several mechanisms for bone disease in IBD. (See  <a class="medical medical_review" href="/z/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a>.)</p><p>Because patients with IBD have an increased risk for vitamin D insufficiency and metabolic bone disease, we suggest focused dietary counseling to ensure adequate intake of vitamin D, with supplementation as needed. The standard recommended intake of vitamin D for individuals with IBD is the same as for healthy individuals  (<a class="graphic graphic_table graphicRef81151" href="/z/d/graphic/81151.html" rel="external">table 4</a>) [<a href="#rid1">1,44,45</a>]. However, we suggest close monitoring of 25-hydroxyvitamin D levels (eg, every 6 to 12 months) and titration of supplements as appropriate to achieve target serum levels. (See  <a class="medical medical_review" href="/z/d/html/2033.html" rel="external">"Overview of vitamin D", section on 'Requirements'</a> and  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"</a>.)</p><p>Several factors contribute to the variability in reported serum 25-hydroxyvitamin D concentrations, including genetic and environmental factors (diet and sun exposure), vitamin D supplements, and factors related to the IBD itself (malabsorption and anorexia). In addition to low serum levels of 25-hydroxyvitamin D, patients with IBD may have abnormal vitamin D metabolism due to inflammatory processes, reflected by lower concentrations of parathyroid hormone (PTH) and 1,25-hydroxyvitamin D [<a href="#rid46">46,47</a>]. These abnormalities improve with appropriate control of inflammation, suggesting that the inflammation has negative effects on PTH, which in turn affects renal 1-alpha-hydroxylase activity. Malabsorption of vitamin D also may play a role, but one study suggests that this occurs in only approximately 10 percent of patients with IBD [<a href="#rid48">48</a>].</p><p>Because vitamin D is involved in regulating the immune system, it has been investigated as a possible adjunctive therapy in IBD [<a href="#rid49">49,50</a>]. There is insufficient evidence to determine if vitamin D supplementation is effective in this role. (See  <a class="medical medical_review" href="/z/d/html/13915.html" rel="external">"Vitamin D and extraskeletal health", section on 'Immune system'</a>.)</p><p class="headingAnchor" id="H1498380207"><span class="h2">Vitamin B12</span><span class="headingEndMark"> — </span>Laboratory evidence of vitamin B12 deficiency has been reported in approximately 20 percent of adult and pediatric patients with Crohn disease [<a href="#rid51">51,52</a>], although it appears to be rare in children with newly diagnosed IBD [<a href="#rid53">53</a>]. Factors contributing to vitamin B12 deficiency include disease or resection of the terminal ileum, gastritis, and bacterial overgrowth. Vitamin B12 deficiency may present with macrocytic anemia or peripheral neuropathy symptoms.</p><p>Serum vitamin B12 levels should be monitored periodically (eg, every 12 to 24 months) in all patients with ileal or ileocolonic resections. Occasional monitoring also may be warranted for patients with ulcerative colitis who have undergone ileal pouch anal anastomosis, due to changes in morphology from small bowel mucosa to large bowel mucosa [<a href="#rid54">54</a>]. If the serum vitamin B12 results are inconclusive or discordant with other clinical features, the diagnosis can be confirmed by measuring serum homocysteine levels and methylmalonic acid. The diagnosis and treatment of this issue is discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">"Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Malabsorption'</a>.)</p><p class="headingAnchor" id="H3461903454"><span class="h2">Zinc</span><span class="headingEndMark"> — </span>As many as 65 percent of patients with Crohn disease have decreased serum zinc concentrations [<a href="#rid53">53,55,56</a>]. However, serum zinc levels vary with albumin and correlate poorly with total body zinc stores; clinically significant zinc deficiency is probably much less common. A deficient state is often reflected by a decreased serum alkaline phosphatase concentration because alkaline phosphatase is a zinc metalloenzyme. In a large prospective registry study, zinc deficiency was associated with increased risk of hospitalization, rate of surgery, and disease-related complications [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/2585.html" rel="external">"Overview of dietary trace elements", section on 'Zinc'</a>.)</p><p>Certain patients with IBD may be at risk for clinically significant zinc deficiency if they have excessive losses due to ostomies, fistulas or profuse diarrhea (eg, &gt;8 watery stools daily), or are on prolonged <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> without trace mineral supplementation. Active inflammatory disease of the small bowel contributes to zinc malabsorption and also may increase losses of endogenous zinc stores via intestinal epithelial sloughing and interruption of reabsorption.</p><p>Several clinical manifestations of zinc deficiency have been described. The dermatologic manifestations are most distinctive, usually consisting of dry, scaly eczematous plaques, often on the face and anogenital area, which may resemble psoriasis. Many other manifestations, such as growth failure, are nonspecific and are more likely to be caused by mechanisms other than zinc deficiency in pediatric patients with IBD. (See  <a class="medical medical_review" href="/z/d/html/5354.html" rel="external">"Zinc deficiency and supplementation in children"</a> and  <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">"Growth failure and pubertal delay in children with inflammatory bowel disease"</a>.)</p><p>For patients with IBD and suspected zinc deficiency (as indicated by low serum levels of zinc and alkaline phosphatase, and risk factors or symptoms of zinc deficiency), we suggest the following approach to zinc supplementation:</p><p class="bulletIndent1"><span class="glyph">●</span>For asymptomatic patients with low serum zinc concentrations, we suggest working with a dietitian to ensure adequate dietary intake or supplementation using maintenance doses of elemental zinc near the recommended dietary allowance (RDA)  (<a class="graphic graphic_table graphicRef51953" href="/z/d/graphic/51953.html" rel="external">table 5</a>). The symptoms of zinc deficiency may be subtle, and zinc supplementation at these doses is generally safe.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with symptoms caused by zinc deficiency (primarily the dermatitis), treat with oral or parenteral zinc at replacement doses of 25 to 50 mg of elemental zinc two to three times daily for two weeks, followed by reassessment of clinical status and serum zinc level. This should be followed by either additional zinc replacement if needed or maintenance dosing near the RDA.</p><p></p><p class="bulletIndent1">Patients with chronic diarrhea should have periodic monitoring of zinc levels and dose adjustment as needed.</p><p></p><p>Because zinc supplementation has been useful in the treatment of chronic diarrhea, it has been suggested that supraphysiologic zinc replacement might be a helpful adjunct to treatment of patients with IBD. A small uncontrolled study of patients with Crohn disease in remission suggested that zinc supplementation reduced intestinal permeability, but the clinical relevance of this finding has not been shown [<a href="#rid58">58</a>]. Zinc is also a common component of antioxidant combinations that are occasionally given to patients with Crohn disease, although there is little evidence to support this practice. (See <a class="local">'Answers to common clinical questions'</a> above.)</p><p class="headingAnchor" id="H3155084330"><span class="h2">Calcium</span><span class="headingEndMark"> — </span>IBD patients often have negative calcium balance, which is reflected in decreased bone mineral density, and also often have inadequate intake of calcium in their diets [<a href="#rid59">59-61</a>]. In a series of women with IBD, 70 percent had inadequate calcium intake [<a href="#rid62">62</a>]. Malabsorption from Crohn disease also can contribute to a calcium deficit. Calcium malabsorption may be caused by vitamin D deficiency, the binding of calcium to undigested fats in the intestinal lumen and rapid transit due to intestinal inflammation and damage, and/or direct effects of glucocorticoids on calcium balance [<a href="#rid63">63</a>]. Many patients restrict their intake of dairy because of concerns about lactose intolerance, resulting in low calcium intake [<a href="#rid64">64</a>]. Other factors also contribute to bone disease in patients with IBD. Calcium malabsorption also predisposes to formation of calcium oxalate kidney stones. (See  <a class="medical medical_review" href="/z/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">"Kidney stones in adults: Epidemiology and risk factors"</a>.)</p><p>The recommended intake of elemental calcium for children and adults with IBD is the same as for the general population [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>1 to 3 years – 700 mg daily</p><p class="bulletIndent1"><span class="glyph">●</span>4 to 8 years – 1000 mg daily</p><p class="bulletIndent1"><span class="glyph">●</span>9 to 18 years – 1300 mg daily</p><p class="bulletIndent1"><span class="glyph">●</span>Men and premenopausal women – 1000 mg daily</p><p class="bulletIndent1"><span class="glyph">●</span>Postmenopausal women and men older than 70 years – 1200 mg daily</p><p></p><p>To minimize risks for metabolic bone disease, patients with IBD should be given focused nutritional counseling and calcium supplementation to meet the recommended target for calcium intake. This is particularly important in patients with additional risk factors for bone disease, which include glucocorticoid therapy and pubertal delay (either current or in the past). In patients with extensive Crohn disease of the small bowel, somewhat higher doses of calcium may be needed. (See  <a class="medical medical_review" href="/z/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/5355.html" rel="external">"Bone health and calcium requirements in adolescents"</a>.)</p><p>Negative calcium balance does not usually cause hypocalcemia, because the bones serve as a reservoir for calcium. Hypoalbuminemia reduces the total plasma calcium concentration but does not affect the physiologically important ionized (free) calcium concentration. If the serum ionized calcium is low, this may be caused by concurrent vitamin D deficiency or hypoparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/845.html" rel="external">"Relation between total and ionized serum calcium concentrations"</a> and  <a class="medical medical_review" href="/z/d/html/840.html" rel="external">"Etiology of hypocalcemia in adults"</a>.)</p><p>The evaluation and management of IBD-associated bone disease in children differs in several respects from that in adults, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Bone mineral density'</a>.)</p><p class="headingAnchor" id="H2381427097"><span class="h1">LESS COMMON DEFICIENCIES</span></p><p class="headingAnchor" id="H4"><span class="h2">Folic acid</span><span class="headingEndMark"> — </span>Folate deficiency may contribute to the development of anemia in patients with IBD, but this is uncommon, except in patients with specific risk factors, which include treatment with <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>.</p><p>Folate deficiency was observed in 20 to 60 percent of adults with IBD in older series but is uncommon in studies from the last decade [<a href="#rid13">13,59</a>]. This historical difference may reflect changes in medical therapy (eg, less use of <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>) and/or higher levels of folate intake through supplements or foods. In modern series of children with newly diagnosed IBD, folate concentrations were normal or higher than those of controls [<a href="#rid53">53,65</a>]. The clinical implications of this finding have yet to be determined.</p><p>Causes of folate deficiency in patients with IBD include insufficient dietary intake [<a href="#rid59">59,65</a>]. In addition, treatment with <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> may exacerbate folate deficiency since the drug's sulfa moiety can bind folate in the gut lumen, leaving it unavailable for absorption. This is not true for other aminosalicylates, such as <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a>. Treatment with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (a <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> antagonist) can also contribute to folate deficiency. Supplementation with folic acid reduces the incidence of liver enzyme abnormalities and methotrexate-associated nausea [<a href="#rid66">66</a>].</p><p>Supplementation of <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> is recommended for IBD patients who are treated with <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and for those with low serum folate levels on laboratory screening. However, there is insufficient evidence to support the use of supplemental folic acid for other patients with IBD. (See  <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease", section on 'Side effects'</a> and  <a class="medical medical_review" href="/z/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Prevention of side effects with folate'</a>.)</p><p>It is unclear if folate supplementation might decrease or increase colorectal cancer risk, based on mixed results of studies in populations without IBD. (See  <a class="medical medical_review" href="/z/d/html/2606.html" rel="external">"Epidemiology and risk factors for colorectal cancer", section on 'Folic acid and folate'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Vitamin A</span><span class="headingEndMark"> — </span>Laboratory evidence of <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> (retinol) deficiency occurs in a substantial proportion of patients with IBD and occasionally is severe enough to cause clinical symptoms. Patients with extensive small bowel involvement and/or fat malabsorption are at increased risk because vitamin A is a fat-soluble vitamin. In one study of adult patients with Crohn disease (40 percent of whom were hospitalized), 5 percent had clinically significant vitamin A deficiency characterized by impaired dark adaptation [<a href="#rid67">67</a>].</p><p>Low serum levels of <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> do not always indicate clinical deficiency, because this finding can be caused by hypoproteinemia and also because serum levels are not well correlated with total body stores. In a small study that used a dose-response test to determine functional vitamin A sufficiency, 37 percent of patients with Crohn disease had abnormal results compared with 12 percent of controls [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/2571.html" rel="external">"Overview of vitamin A", section on 'Measurement'</a>.)</p><p>Patients with laboratory evidence of <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> deficiency who are asymptomatic should be managed by optimizing treatment for the IBD and ensuring recommended intake of the vitamin  (<a class="graphic graphic_table graphicRef81151" href="/z/d/graphic/81151.html" rel="external">table 4</a>), with further monitoring to ensure that levels normalize. Patients with ocular symptoms or severe malnutrition should be further evaluated for xerophthalmia and treated with replacement doses of vitamin A. (See  <a class="medical medical_review" href="/z/d/html/2571.html" rel="external">"Overview of vitamin A", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/2571.html" rel="external">"Overview of vitamin A", section on 'Targeted supplementation for disease'</a>.)</p><p>Excessive <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> supplementation should be avoided because high intakes of vitamin A are associated with an increased risk of bone fractures, as well as other effects including pseudotumor cerebri. (See  <a class="medical medical_review" href="/z/d/html/2571.html" rel="external">"Overview of vitamin A", section on 'Adverse effects on bone'</a>.)</p><p><a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">Vitamin A</a> is considered an antioxidant, but there is no clear evidence that deficiency of this or other antioxidants are involved in the pathogenesis of inflammation in IBD. (See <a class="local">'Answers to common clinical questions'</a> above.)</p><p class="headingAnchor" id="H10"><span class="h2">Vitamin E</span><span class="headingEndMark"> — </span>Laboratory evidence of <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> (alpha-tocopherol) deficiency is unusual in IBD, and clinically significant deficiency is rare. In one study, mean levels of vitamin E were lower in adult patients with IBD compared with healthy controls [<a href="#rid69">69</a>]. In another study, 6 percent of children with IBD had low serum levels of vitamin E (defined as &lt;5 mg/L), and this was correlated with disease activity [<a href="#rid70">70</a>]. Mechanisms for vitamin E deficiency in IBD include fat malabsorption and low dietary intake. The majority of individuals with IBD consume less than the recommended intake of vitamin E [<a href="#rid59">59,71</a>].</p><p>The recommended intake of <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> for most patients with IBD is the same as for a healthy population, which is expressed as the dietary reference intake (DRI) in the United States  (<a class="graphic graphic_table graphicRef81151" href="/z/d/graphic/81151.html" rel="external">table 4</a>) [<a href="#rid72">72</a>]. High-dose vitamin E supplementation is not necessary or recommended, because it may be associated with increased mortality in individuals without IBD [<a href="#rid12">12</a>]. Patients with significant fat malabsorption may need a water-soluble form of vitamin E supplements and/or higher doses, titrated to achieve normal serum levels. (See  <a class="medical medical_review" href="/z/d/html/2582.html" rel="external">"Overview of vitamin E", section on 'Requirements'</a> and  <a class="medical medical_review" href="/z/d/html/2582.html" rel="external">"Overview of vitamin E", section on 'Risks and benefits of supplementation'</a>.)</p><p>The DRI refers to alpha-tocopherol, which is the primary bioactive form of <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>, but gamma-tocopherol and several related compounds have been described. Both alpha- and gamma-tocopherol exhibit antiinflammatory properties. Vitamin E acts as a free radical scavenger, protecting cell membranes from peroxidation. It has been suggested that depletion of vitamin E and other antioxidant vitamins may contribute to the pathogenesis of IBD, but such pathways have not been established. (See <a class="local">'Answers to common clinical questions'</a> above.)</p><p class="headingAnchor" id="H11"><span class="h2">Vitamin K</span><span class="headingEndMark"> — </span>Biochemical evidence of vitamin K deficiency (based on measurements of protein induced by vitamin K absence-II [PIVKA-II]) have been reported in more than 40 percent of children with IBD [<a href="#rid73">73</a>]. In a series of adult patients with IBD, evidence of vitamin K deficiency was seen in 25 percent of those with Crohn disease but in only 4 percent of those with ulcerative colitis [<a href="#rid74">74</a>]. Contributing mechanisms may include decreased intake due to anorexia or dietary restrictions, fat malabsorption (particularly with terminal ileal disease or resection), and/or antibiotics (which interfere with vitamin K production by intestinal bacteria). (See  <a class="medical medical_review" href="/z/d/html/2624.html" rel="external">"Overview of vitamin K"</a>.)</p><p>Vitamin K is a cofactor in the carboxylation of osteocalcin, a protein essential for calcium binding to bone. Vitamin K deficiency may be a cause of decreased bone mineral density in patients with Crohn disease [<a href="#rid74">74-77</a>]. However, this association is confounded by disease activity and corticosteroid exposures. Whether supplementation with vitamin K in patients with IBD can help prevent or treat bone disease has not been established. (See  <a class="medical medical_review" href="/z/d/html/2036.html" rel="external">"Drugs that affect bone metabolism", section on 'Warfarin'</a> and  <a class="medical medical_review" href="/z/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H1017195899"><span class="h2">Other</span><span class="headingEndMark"> — </span>Deficiencies of the following nutrients occasionally occur in patients with IBD and reflect generalized malnutrition rather than specific risks from IBD. Recommended intake and upper limits for selenium, copper, and other trace minerals are shown in the table  (<a class="graphic graphic_table graphicRef51953" href="/z/d/graphic/51953.html" rel="external">table 5</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selenium</strong> – Selenium concentration in whole blood and glutathione peroxidase activity are often somewhat lower in adults or children with IBD compared with healthy individuals, but biochemical or clinical evidence of deficiency is rare [<a href="#rid78">78-80</a>]. Deficient levels of selenium are more common among patients with Crohn disease who have undergone small bowel resection of &gt;200 cm, those receiving enteral nutrition supplementation [<a href="#rid81">81-83</a>], and patients receiving long-term <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> without trace minerals [<a href="#rid84">84-86</a>].</p><p></p><p class="bulletIndent1">Selenium occurs naturally in meats, cereals, and fish. It has multiple biologic roles. It is a component of the antioxidant glutathione peroxidase and is also required for formation of thyroid hormone. Clinical manifestations of prolonged selenium deficiency include erythrocyte macrocytosis and muscle dysfunction, cardiomyopathy, and encephalitis. (See  <a class="medical medical_review" href="/z/d/html/2585.html" rel="external">"Overview of dietary trace elements", section on 'Selenium'</a>.)</p><p></p><p class="bulletIndent1">Like zinc, <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a> may be included in the antioxidant combinations that are occasionally given to patients with Crohn disease, although there is little firm evidence to support this practice. (See <a class="local">'Answers to common clinical questions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phosphate</strong> – Malnourished patients with Crohn disease and chronic diarrhea are at risk for hypophosphatemia and require close monitoring and phosphate replacement. Phosphate stores can be depleted in patients with chronic diarrhea because of malabsorption of phosphate and vitamin D. In malnourished patients, sudden increases in nutrition can cause acute hypophosphatemia (refeeding syndrome), which is uncommon in patients with IBD but can potentially result in life-threatening complications due to acute fluid and electrolyte shifts. Poor intake alone is rarely responsible for phosphate depletion because of rapid renal adaptation. (See  <a class="medical medical_review" href="/z/d/html/830.html" rel="external">"Hypophosphatemia: Causes of hypophosphatemia"</a> and  <a class="medical medical_review" href="/z/d/html/15778.html" rel="external">"Anorexia nervosa in adults and adolescents: The refeeding syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Copper</strong> – Most adults and children with IBD do not demonstrate copper deficiency; indeed, some series report relatively high copper levels [<a href="#rid55">55,79,80,83,87</a>]. However, increased losses are observed in those with profuse diarrhea, or high-output fistulas or ostomies (eg, &gt;8 watery stools daily, or ostomy output &gt;1500 mL/day or &gt;20 mL/kg/day in children), or those maintained on <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> without mineral supplements [<a href="#rid88">88,89</a>]. Because copper and zinc are competitively absorbed from the jejunum, high doses of zinc (eg, from prolonged ingestion of zinc supplements) can result in copper deficiency. (See  <a class="medical medical_review" href="/z/d/html/2585.html" rel="external">"Overview of dietary trace elements"</a>.)</p><p></p><p class="bulletIndent1">Copper is an essential trace element used in many enzyme complexes and is required for normal iron absorption. Clinical manifestations of copper deficiency include abnormally formed hair, depigmentation of the skin, and microcytic anemia. The neurologic manifestations include ataxia, neuropathy, and cognitive deficits that can mimic vitamin B12 deficiency. (See  <a class="medical medical_review" href="/z/d/html/2585.html" rel="external">"Overview of dietary trace elements", section on 'Copper'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnesium</strong> – Magnesium deficiency in patients with IBD may result from decreased oral intake, malabsorption, or increased intestinal losses [<a href="#rid90">90,91</a>]. Chronic magnesium deficiency may contribute to osteopenia, fatigue, and muscle cramps. (See  <a class="medical medical_review" href="/z/d/html/848.html" rel="external">"Hypomagnesemia: Clinical manifestations of magnesium depletion"</a>.)</p><p></p><p class="bulletIndent1">Mild or chronic deficiencies can be supplemented orally with <a class="drug drug_general" data-topicid="10122" href="/z/d/drug information/10122.html" rel="external">magnesium chloride</a>. However, large doses given orally can lead to diarrhea, so parenteral administration of magnesium may be necessary in patients with very low serum magnesium levels.</p><p></p><p class="headingAnchor" id="H3595573048"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111044.html" rel="external">"Society guideline links: Pediatric iron deficiency"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/113229.html" rel="external">"Society guideline links: Inflammatory bowel disease in children"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110557.html" rel="external">"Society guideline links: Vitamin deficiencies"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical relevance</strong> – Historically, nutritional deficiencies or the inability to maintain ideal body weight were common in adults with inflammatory bowel disease (IBD) and especially those with Crohn disease. Mechanisms include reduced nutrient intake, malabsorption, increased energy expenditure, and enteral loss. Advances in diagnosis and medical therapy have decreased the incidence of this problem. These issues continue to be a concern in children with IBD, due to increased nutrient needs during growth and development. (See  <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">"Growth failure and pubertal delay in children with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for nutrient deficiencies</strong> – The risk for vitamin and mineral deficiencies in IBD depends on the type of disease (most are more common in Crohn disease than in ulcerative colitis), disease activity, disease location, age (growing children are at increased risk), and surgical bowel resection  (<a class="graphic graphic_table graphicRef72725" href="/z/d/graphic/72725.html" rel="external">table 1</a>). In particular:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Iron deficiency is clinically important and common, especially in patients with chronic or acute gastrointestinal blood loss and/or high levels of disease activity, or those who have had intestinal resection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vitamin B12 or fat-soluble vitamin deficiency sometimes develops in patients with active disease or resection of the terminal ileum.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Zinc deficiency may develop in patients with extensive disease of the small intestine with profuse diarrhea. (See <a class="local">'Risk factors for nutrient deficiencies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory monitoring</strong> – Routine laboratory studies indicated for nutritional assessment in patients with IBD are outlined in the table  (<a class="graphic graphic_table graphicRef66288" href="/z/d/graphic/66288.html" rel="external">table 2</a>). (See <a class="local">'Laboratory monitoring for nutrient deficiencies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The most important strategy to address micronutrient deficiencies is to treat the patient's underlying disease to address inflammation and any associated malabsorption and anorexia. Patients with specific, pronounced deficiencies may require vitamin or mineral supplements, tailored to their individual needs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anemia</strong> – Anemia in patients with IBD is often related to iron deficiency but may also be caused by anemia of chronic inflammation (anemia of chronic disease). Occasionally, it is caused by vitamin B12 or folate deficiency, medications, or multiple mechanisms. Laboratory tests sometimes help to distinguish among these causes, but a trial of iron therapy is necessary to confirm a diagnosis of iron deficiency anemia. (See <a class="local">'Considerations for patients with anemia'</a> above and <a class="local">'Assessment'</a> above.)</p><p></p><p class="bulletIndent2">For patients with mild IBD activity and mild or moderate anemia (hemoglobin 10 to 12 g/dL in children and women or 10 to 13 g/dL in men), we suggest low-dose iron supplementation by the oral route as an initial trial (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For those with moderate to severe IBD activity or severe anemia (hemoglobin &lt;10 g/dL), or for those who do not tolerate or respond appropriately to oral iron, we suggest intravenous (IV) iron supplementation (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). The decision to use the oral versus IV route may also depend on patient preference or cost considerations. We commonly use IV iron because it is effective and safe. Several formulations of IV iron are available that have established efficacy and safety in this population. (See <a class="local">'Iron therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone disease</strong> – Bone disease (osteopenia or osteoporosis) is an insidious but common complication of IBD. Important contributors to bone disease include malnutrition (particularly calcium and vitamin D deficiency), glucocorticoid treatment, active inflammation, and pubertal delay.</p><p></p><p class="bulletIndent2">All patients with IBD should be counseled to ensure recommended intake of calcium (1300 mg daily in adolescents and 1000 to 1200 mg daily in adults) and vitamin D (600 international units [15 mcg] daily) and monitored for vitamin D deficiency. (See <a class="local">'Vitamin D'</a> above and <a class="local">'Calcium'</a> above and  <a class="medical medical_review" href="/z/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a>.)</p><p></p><p class="headingAnchor" id="H2506619967"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jonathan Teitelbaum, MD, who contributed to earlier versions of this topic review. </p><p>The UpToDate editorial staff also acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Ross AC, Taylor Cl, Yaktine AL, Del Valle HB. Institute of Medicine/National Academies Press/Food and Nutrition Board. Dietary Reference Intakes of Calcium and Vitamin D. 2010. Available at: http://books.nap.edu/openbook.php?record_id=13050 (Accessed on December 02, 2010).</li><li><a class="nounderline abstract_t">Suskind DL, Cohen SA, Brittnacher MJ, et al. Clinical and Fecal Microbial Changes With Diet Therapy in Active Inflammatory Bowel Disease. J Clin Gastroenterol 2018; 52:155.</a></li><li><a class="nounderline abstract_t">Cohen SA, Gold BD, Oliva S, et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2014; 59:516.</a></li><li><a class="nounderline abstract_t">Braly K, Williamson N, Shaffer ML, et al. Nutritional Adequacy of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2017; 65:533.</a></li><li><a class="nounderline abstract_t">Levine A, Wine E, Assa A, et al. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology 2019; 157:440.</a></li><li><a class="nounderline abstract_t">Rizvi S, Schoen RE. Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap? Am J Gastroenterol 2011; 106:1872.</a></li><li><a class="nounderline abstract_t">Harvey RS, Reffitt DM, Doig LA, et al. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther 1998; 12:845.</a></li><li><a class="nounderline abstract_t">Wendland BE, Aghdassi E, Tam C, et al. Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. Am J Clin Nutr 2001; 74:259.</a></li><li><a class="nounderline abstract_t">Aghdassi E, Wendland BE, Steinhart AH, et al. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. a randomized controlled trial. Am J Gastroenterol 2003; 98:348.</a></li><li><a class="nounderline abstract_t">Trebble TM, Stroud MA, Wootton SA, et al. High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial. Br J Nutr 2005; 94:253.</a></li><li><a class="nounderline abstract_t">Geerling BJ, Badart-Smook A, van Deursen C, et al. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 2000; 6:77.</a></li><li><a class="nounderline abstract_t">Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012; :CD007176.</a></li><li><a class="nounderline abstract_t">Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006; 24:1507.</a></li><li><a class="nounderline abstract_t">Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008; 103:1299.</a></li><li><a class="nounderline abstract_t">Goyal A, Zheng Y, Albenberg LG, et al. Anemia in Children With Inflammatory Bowel Disease: A Position Paper by the IBD Committee of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2020; 71:563.</a></li><li><a class="nounderline abstract_t">Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53:1190.</a></li><li><a class="nounderline abstract_t">Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012; 1823:1434.</a></li><li><a class="nounderline abstract_t">Katsanos K, Cavalier E, Ferrante M, et al. Intravenous iron therapy restores functional iron deficiency induced by infliximab. J Crohns Colitis 2007; 1:97.</a></li><li><a class="nounderline abstract_t">Gasché C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997; 126:782.</a></li><li><a class="nounderline abstract_t">Gasche C, Dejaco C, Reinisch W, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion 1999; 60:262.</a></li><li><a class="nounderline abstract_t">Fritz J, Walia C, Elkadri A, et al. A Systematic Review of Micronutrient Deficiencies in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2019; 25:445.</a></li><li><a class="nounderline abstract_t">Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006; 12:123.</a></li><li><a class="nounderline abstract_t">Cronin CC, Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol 2001; 96:2296.</a></li><li><a class="nounderline abstract_t">Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13:1545.</a></li><li><a class="nounderline abstract_t">Crary SE, Hall K, Buchanan GR. Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. Pediatr Blood Cancer 2011; 56:615.</a></li><li><a class="nounderline abstract_t">Plummer ES, Crary SE, McCavit TL, Buchanan GR. Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. Pediatr Blood Cancer 2013; 60:1747.</a></li><li><a class="nounderline abstract_t">Danko I, Weidkamp M. Correction of Iron Deficiency Anemia With Intravenous Iron Sucrose in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2016; 63:e107.</a></li><li><a class="nounderline abstract_t">Bevers N, Van de Vijver E, Aliu A, et al. Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease: The POPEYE Randomized Controlled Clinical Trial. J Pediatr 2023; 256:113.</a></li><li><a class="nounderline abstract_t">Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996; 334:619.</a></li><li><a class="nounderline abstract_t">Gasche C, Waldhoer T, Feichtenschlager T, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 2001; 96:2382.</a></li><li><a class="nounderline abstract_t">Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40:1058.</a></li><li><a class="nounderline abstract_t">de Silva AD, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflamm Bowel Dis 2003; 9:316.</a></li><li><a class="nounderline abstract_t">Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009; 44:838.</a></li><li><a class="nounderline abstract_t">Reinisch W, Chowers Y, Danese S, et al. The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther 2013; 38:1109.</a></li><li><a class="nounderline abstract_t">Gasche C, Evstatiev R, Haas T, et al. [Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party]. Z Gastroenterol 2011; 49:627.</a></li><li><a class="nounderline abstract_t">Stein J, Bager P, Befrits R, et al. Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. Eur J Gastroenterol Hepatol 2013; 25:1456.</a></li><li><a class="nounderline abstract_t">Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9:211.</a></li><li><a class="nounderline abstract_t">García-López S, Bocos JM, Gisbert JP, et al. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfus 2016; 14:199.</a></li><li><a class="nounderline abstract_t">Jimenez K, Gasche C, Auerbach M. On both sides of the ocean. Blood Transfus 2016; 14:197.</a></li><li><a class="nounderline abstract_t">Driscoll RH Jr, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982; 83:1252.</a></li><li><a class="nounderline abstract_t">Pappa HM, Grand RJ, Gordon CM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis 2006; 12:1162.</a></li><li><a class="nounderline abstract_t">Sentongo TA, Semaeo EJ, Stettler N, et al. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr 2002; 76:1077.</a></li><li><a class="nounderline abstract_t">Pappa HM, Langereis EJ, Grand RJ, Gordon CM. Prevalence and risk factors for hypovitaminosis D in young patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53:361.</a></li><li><a class="nounderline abstract_t">Kleinman RE, Baldassano RN, Caplan A, et al. Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology And Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:15.</a></li><li><a class="nounderline abstract_t">American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:791.</a></li><li><a class="nounderline abstract_t">Prosnitz AR, Leonard MB, Shults J, et al. Changes in vitamin D and parathyroid hormone metabolism in incident pediatric Crohn's disease. Inflamm Bowel Dis 2013; 19:45.</a></li><li><a class="nounderline abstract_t">Augustine MV, Leonard MB, Thayu M, et al. Changes in vitamin D-related mineral metabolism after induction with anti-tumor necrosis factor-α therapy in Crohn's disease. J Clin Endocrinol Metab 2014; 99:E991.</a></li><li><a class="nounderline abstract_t">Vogelsang H, Schöfl R, Tillinger W, et al. 25-hydroxyvitamin D absorption in patients with Crohn's disease and with pancreatic insufficiency. Wien Klin Wochenschr 1997; 109:678.</a></li><li><a class="nounderline abstract_t">Nicholson I, Dalzell AM, El-Matary W. Vitamin D as a therapy for colitis: a systematic review. J Crohns Colitis 2012; 6:405.</a></li><li><a class="nounderline abstract_t">Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010; 32:377.</a></li><li><a class="nounderline abstract_t">Seidman E, LeLeiko N, Ament M, et al. Nutritional issues in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991; 12:424.</a></li><li><a class="nounderline abstract_t">Headstrom PD, Rulyak SJ, Lee SD. Prevalence of and risk factors for vitamin B(12) deficiency in patients with Crohn's disease. Inflamm Bowel Dis 2008; 14:217.</a></li><li><a class="nounderline abstract_t">Alkhouri RH, Hashmi H, Baker RD, et al. Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 56:89.</a></li><li><a class="nounderline abstract_t">Shen B, Remzi FH, Lavery IC, et al. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin Gastroenterol Hepatol 2008; 6:145.</a></li><li><a class="nounderline abstract_t">Filippi J, Al-Jaouni R, Wiroth JB, et al. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis 2006; 12:185.</a></li><li><a class="nounderline abstract_t">McClain C, Soutor C, Zieve L. Zinc deficiency: a complication of Crohn's disease. Gastroenterology 1980; 78:272.</a></li><li><a class="nounderline abstract_t">Siva S, Rubin DT, Gulotta G, et al. Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017; 23:152.</a></li><li><a class="nounderline abstract_t">Sturniolo GC, Di Leo V, Ferronato A, et al. Zinc supplementation tightens "leaky gut" in Crohn's disease. Inflamm Bowel Dis 2001; 7:94.</a></li><li><a class="nounderline abstract_t">Vagianos K, Bector S, McConnell J, Bernstein CN. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr 2007; 31:311.</a></li><li><a class="nounderline abstract_t">Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795.</a></li><li><a class="nounderline abstract_t">van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 2006; :59.</a></li><li><a class="nounderline abstract_t">Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol 2003; 98:2468.</a></li><li><a class="nounderline abstract_t">Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112:352.</a></li><li><a class="nounderline abstract_t">Vernia P, Loizos P, Di Giuseppantonio I, et al. Dietary calcium intake in patients with inflammatory bowel disease. J Crohns Colitis 2014; 8:312.</a></li><li><a class="nounderline abstract_t">Heyman MB, Garnett EA, Shaikh N, et al. Folate concentrations in pediatric patients with newly diagnosed inflammatory bowel disease. Am J Clin Nutr 2009; 89:545.</a></li><li><a class="nounderline abstract_t">Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2013; :CD000951.</a></li><li><a class="nounderline abstract_t">Main AN, Mills PR, Russell RI, et al. Vitamin A deficiency in Crohn's disease. Gut 1983; 24:1169.</a></li><li><a class="nounderline abstract_t">Soares-Mota M, Silva TA, Gomes LM, et al. High prevalence of vitamin A deficiency in Crohn's disease patients according to serum retinol levels and the relative dose-response test. World J Gastroenterol 2015; 21:1614.</a></li><li><a class="nounderline abstract_t">Figueiredo C, Van Doorn LJ, Nogueira C, et al. Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains. Scand J Gastroenterol 2001; 36:128.</a></li><li><a class="nounderline abstract_t">Bousvaros A, Zurakowski D, Duggan C, et al. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J Pediatr Gastroenterol Nutr 1998; 26:129.</a></li><li><a class="nounderline abstract_t">Hengstermann S, Valentini L, Schaper L, et al. Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease. Clin Nutr 2008; 27:571.</a></li><li class="breakAll">Food and Nutrition Board of the Institute of Medicine. DRI Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. National Academies Press, Washington DC, 2000. p. 186. Available at: http://books.nap.edu/catalog.php?record_id=9810#toc (Accessed on October 01, 2018).</li><li><a class="nounderline abstract_t">Nowak JK, Grzybowska-Chlebowczyk U, Landowski P, et al. Prevalence and correlates of vitamin K deficiency in children with inflammatory bowel disease. Sci Rep 2014; 4:4768.</a></li><li><a class="nounderline abstract_t">Kuwabara A, Tanaka K, Tsugawa N, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int 2009; 20:935.</a></li><li><a class="nounderline abstract_t">Duggan P, O'Brien M, Kiely M, et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol 2004; 99:2178.</a></li><li><a class="nounderline abstract_t">Schoon EJ, Müller MC, Vermeer C, et al. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 2001; 48:473.</a></li><li><a class="nounderline abstract_t">Nakajima S, Iijima H, Egawa S, et al. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. Nutrition 2011; 27:1023.</a></li><li><a class="nounderline abstract_t">Thomson CD, Rea HM, Doesburg VM, Robinson MF. Selenium concentrations and glutathione peroxidase activities in whole blood of New Zealand residents. Br J Nutr 1977; 37:457.</a></li><li><a class="nounderline abstract_t">Ojuawo A, Keith L. The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease. Cent Afr J Med 2002; 48:116.</a></li><li><a class="nounderline abstract_t">Ringstad J, Kildebo S, Thomassen Y. Serum selenium, copper, and zinc concentrations in Crohn's disease and ulcerative colitis. Scand J Gastroenterol 1993; 28:605.</a></li><li><a class="nounderline abstract_t">Rannem T, Ladefoged K, Hylander E, et al. Selenium status in patients with Crohn's disease. Am J Clin Nutr 1992; 56:933.</a></li><li><a class="nounderline abstract_t">Kuroki F, Matsumoto T, Iida M. Selenium is depleted in Crohn's disease on enteral nutrition. Dig Dis 2003; 21:266.</a></li><li><a class="nounderline abstract_t">Johtatsu T, Andoh A, Kurihara M, et al. Serum concentrations of trace elements in patients with Crohn's disease receiving enteral nutrition. J Clin Biochem Nutr 2007; 41:197.</a></li><li><a class="nounderline abstract_t">Quercia RA, Korn S, O'Neill D, et al. Selenium deficiency and fatal cardiomyopathy in a patient receiving long-term home parenteral nutrition. Clin Pharm 1984; 3:531.</a></li><li><a class="nounderline abstract_t">Kawakubo K, Iida M, Matsumoto T, et al. Progressive encephalopathy in a Crohn's disease patient on long-term total parenteral nutrition: possible relationship to selenium deficiency. Postgrad Med J 1994; 70:215.</a></li><li><a class="nounderline abstract_t">Ishida T, Himeno K, Torigoe Y, et al. Selenium deficiency in a patient with Crohn's disease receiving long-term total parenteral nutrition. Intern Med 2003; 42:154.</a></li><li><a class="nounderline abstract_t">Geerling BJ, Badart-Smook A, Stockbrügger RW, Brummer RJ. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr 1998; 67:919.</a></li><li><a class="nounderline abstract_t">Goldschmid S, Graham M. Trace element deficiencies in inflammatory bowel disease. Gastroenterol Clin North Am 1989; 18:579.</a></li><li><a class="nounderline abstract_t">Spiegel JE, Willenbucher RF. Rapid development of severe copper deficiency in a patient with Crohn's disease receiving parenteral nutrition. JPEN J Parenter Enteral Nutr 1999; 23:169.</a></li><li><a class="nounderline abstract_t">Galland L. Magnesium and inflammatory bowel disease. Magnesium 1988; 7:78.</a></li><li><a class="nounderline abstract_t">Habtezion A, Silverberg MS, Parkes R, et al. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002; 8:87.</a></li></ol></div><div id="topicVersionRevision">Topic 5887 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://books.nap.edu/openbook.php?record_id=13050" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ross AC, Taylor Cl, Yaktine AL, Del Valle HB. Institute of Medicine/National Academies Press/Food and Nutrition Board. Dietary Reference Intakes of Calcium and Vitamin D. 2010. Available at: http://books.nap.edu/openbook.php?record_id=13050 (Accessed on December 02, 2010).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28030510" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical and Fecal Microbial Changes With Diet Therapy in Active Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24897165" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28825603" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Nutritional Adequacy of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31170412" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22056566" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9768526" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11470730" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12591053" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16115360" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10833065" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419320" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17206940" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Systematic review: managing anaemia in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477354" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32947565" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anemia in Children With Inflammatory Bowel Disease: A Position Paper by the IBD Committee of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15247190" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Iron, anaemia, and inflammatory bowel diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22306005" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hepcidin and iron homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21172191" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intravenous iron therapy restores functional iron deficiency induced by infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9148651" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10343140" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30137322" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A Systematic Review of Micronutrient Deficiencies in Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16432377" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11513165" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Anemia in patients with chronic inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17985376" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21298748" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23832487" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27540710" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Correction of Iron Deficiency Anemia With Intravenous Iron Sucrose in Children With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36563900" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease: The POPEYE Randomized Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592524" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11513178" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16165718" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14555915" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19330567" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24099472" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21526463" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : [Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24100539" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25518052" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27177405" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27177396" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : On both sides of the ocean.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6982188" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Vitamin D deficiency and bone disease in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17119391" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399281" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Vitamin D status in children, adolescents, and young adults with Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21613964" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevalence and risk factors for hypovitaminosis D in young patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187775" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology And Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612916" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22488969" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Changes in vitamin D and parathyroid hormone metabolism in incident pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24617709" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Changes in vitamin D-related mineral metabolism after induction with anti-tumor necrosis factor-αtherapy in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9331957" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : 25-hydroxyvitamin D absorption in patients with Crohn's disease and with pancreatic insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22398085" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vitamin D as a therapy for colitis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20491740" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1678007" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Nutritional issues in pediatric inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17886286" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prevalence of and risk factors for vitamin B(12) deficiency in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22832510" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Vitamin and mineral status in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18237865" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534419" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Nutritional deficiencies in patients with Crohn's disease in remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7350050" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Zinc deficiency: a complication of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27930412" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11383597" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Zinc supplementation tightens "leaky gut" in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17595441" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Nutrition assessment of patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612917" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : AGA technical review on osteoporosis in gastrointestinal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16782623" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Skeletal morbidity in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638350" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2407167" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Glucocorticoid-induced osteoporosis: pathogenesis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24090907" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Dietary calcium intake in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19116333" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Folate concentrations in pediatric patients with newly diagnosed inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23728635" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6685675" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Vitamin A deficiency in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25663781" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : High prevalence of vitamin A deficiency in Crohn's disease patients according to serum retinol levels and the relative dose-response test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11252403" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9481625" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316141" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316141" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24759680" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prevalence and correlates of vitamin K deficiency in children with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18825300" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15555000" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Vitamin K status in patients with Crohn's disease and relationship to bone turnover.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11247890" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482072" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/861195" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Selenium concentrations and glutathione peroxidase activities in whole blood of New Zealand residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14562534" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8362213" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Serum selenium, copper, and zinc concentrations in Crohn's disease and ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1415013" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Selenium status in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14571102" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Selenium is depleted in Crohn's disease on enteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299716" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Serum concentrations of trace elements in patients with Crohn's disease receiving enteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6435941" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Selenium deficiency and fatal cardiomyopathy in a patient receiving long-term home parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8183758" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Progressive encephalopathy in a Crohn's disease patient on long-term total parenteral nutrition: possible relationship to selenium deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12636234" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Selenium deficiency in a patient with Crohn's disease receiving long-term total parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9583850" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2680967" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Trace element deficiencies in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10338225" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Rapid development of severe copper deficiency in a patient with Crohn's disease receiving parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3294519" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Magnesium and inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11854605" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Risk factors for low bone density in Crohn's disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
